Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Complementary and alternative medicine in multiple sclerosis.
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
MRI in multiple sclerosis: a review of the current literature.
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
Evidence-based guideline: Assessment and management of psychiatric disorders in individuals with MS: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).
Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis.
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.
FDA approves Ampyra to improve walking in adults with multiple sclerosis
MP2RAGE Multiple Sclerosis Magnetic Resonance Imaging at 3 T.
[Controlled research on multiple sclerosis treated with electroacupuncture and acupoint injection].
Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study.
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
In vivo evidence of glutamate toxicity in multiple sclerosis.
Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Ampyra (dalfampridine) medication guide
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Assessment of confirmed urinary tract infection in patients treated with dalfampridine for multiple sclerosis.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.
Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
Energy Cost of Walking and Its Association With Gait Parameters, Daily Activity, and Fatigue in Persons With Mild Multiple Sclerosis.

Pages